AzTrials
AzTrials

Procedural SedationPhase 1NCT03860831

Intranasal Ketamine and Midazolam Mixture for Procedural Sedation in Children With Mental Disabilities:

A Phase 1 study testing Ketamine + midazolam in people with Procedural Sedation, run by Ain Shams University at 2 sites in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Ketamine and Midazolam are well known sedative drugs that can be given through different routes such as intravenous, intramuscular, oral, rectal and intranasal route. Anesthetic staff usually prefer intravenous route but sometimes inserting venous access is difficult in uncooperative mentally disabled children. Read more about this study

Who is it for?
Ages 4 to 12 years
Conditions the study is for
Procedural Sedation
What is being tested?
Ketamine + midazolam
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
2 sitesEgypt
Study dates
6 Mar 2019to Jul 2019
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 to 12 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Mentally affected children (autism,down syndrome and cerebral palsy)
  • children who are scheduled for Short procedures (30 minutes or less) under sedation

Who cannot join

  • parents refusal.
  • child cooperation and acceptance of venipuncture or cannula in situ.
  • children with known allergy to ketamine or midazolam.
  • liver or renal organ dysfunction.
  • suspected difficult cannulation.
  • congenital heart disease.
Show all 10Show fewer
  • active pulmonary infection or asthma.
  • increased intracranial tension or intraocular pressure.
  • severe trauma0
  • significant nasal discharge or obstruction.

Trial locations and contacts

2 sites in 1 country.

dean of faculty of medicine, MD contact

0020224821894

dean@med.asu.edu.eg

vice of research of fuclty of medicine contact

0020226857539

viced.research@med.asu.edu.eg

Egypt2 sites, 2 recruiting
  • Sanaa Farag Mahmoud

    Cairo, New Cairo, 11835

    sanaa wasfy, lecturer, 01061262757, sanaawasfy@gmail.com

    Recruiting
  • Ainshams hospitals

    Cairo, 11591

    sanaa fFM wasfy, MD, 00201061262757, sanaawasfy@gmail.com

    wael SO osman, MD, 00201282269727, waelbehairy@yahoo.com

    Not yet recruiting

Other trials in Egypt

About this study

Official title: Lecturer of Anesthesia ,Intensive Care and Pain Management in Faculty of Medicine Ain Shams University

Ketamine and Midazolam are well known sedative drugs that can be given through different routes such as intravenous, intramuscular, oral, rectal and intranasal route. Anesthetic staff usually prefer intravenous route but sometimes inserting venous access is difficult in uncooperative mentally disabled children. Intranasal ketamine+Midazolam can be a needless effective alternative in these vulnerable patients

Read the detailed description

Sedation and analgesia decreases the need for general anesthesia outside the operating room. Intravenous route is the standard way of sedation, but its use can be limited in uncooperative mentally disabled children. Active Physical restraint of children causes emotional trauma for both parents and children particularly in these patients. Oral sedation has multiple disadvantages as delayed onset of action, better taste, the need of different types of syrup or honey according to the preference of the patient, children may refuse to take oral drugs or even spit it and it also causes postoperative nausea and vomiting. In contrast, intramuscular sedation is an easy effective way of administration and it is preferred due to its rapid onset of action and higher predictability of the duration, however, fear of the pain of injections is considered a disadvantage in this vulnerable pediatric patients. nasal route is an important alternative route because it is a painless and needless approach with rapid drug absorption from nasal mucosa reaching the cerebrospinal fluid and bypassing the first pass metabolism in the liver. Intranasal midazolam for sedation of children was first described by Wilton et al .Recently studies proved the use of nasal ketamine spray for treatment of resistant depression in adults. Ketamine as a premedication in children has been also successfully given through the nasal route. In Ain shams University hospitals we give either oral Midazolam or intramuscular Ketamine followed by sevoflurane or propofol for pediatric procedural sedation. Nasal Midazolam or Ketamine has not been tried despite being a feasible choice with many possible advantages. Combination of ketamine and midazolam causes deeper sedation and less dysphoric reaction of ketamine so in this study, we evaluate the efficacy and safety of administration of this combination through intranasal route for procedural sedation in children with mental developmental delay outside the operating room.

After approval from our Ethical Committee, written informed consent from the parents will be taken. Forty children presented with autism,mongolism or cerebral palsy classified as American Society of Anesthesiologists (ASA) physical status I and II, aged between 4 and 12 years will be enrolled in our study, and computer-generated assignment will be used for randomization and to allocate patients to one of two equal study groups.

patients will fulfill the fasting hours if elective while the patients in ER will be asked to wait for six hours after last meal.

Patients will be divided into two groups Group IN:will receive intranasal ketamine 5 mg/kg and midazolam 0.2 mg/kg, and we will give intranasal sedatives by using mucosal atomisation device.

Group IM:will receive intramuscular ketamine 5 mg/kg, and midazolam 0.2 mg/kg Sedation levels after 10, 20, and 30 min will be evaluated by Pediatric Sedation State Scale (PSSS).

Drugs will be given 15- 20 minutes before procedure then Heart rate (HR), Oxygen saturation (Spo2), and mean arterial blood pressure (MBP) will be continuously monitored and recorded every 5 min after drug administration for 60 minutes .

Local anesthesia will be given in painful procedures. Intravenous ketamine 1 mg/kg will be given if needed due to prolongation of procedure or if required sedation level not reached through intranasal or intramuscular route.

respiratory events as airway obstruction and desaturation less than 92% will be treated by jaw thrust and oxygen supplementation, apnea or laryngeal spasm will be managed with endotracheal intubation. Wheezing will be recorded and properly managed with bronchodilators and steroids.

Emergency cart and drugs will be available for haemodynamic and respiratory instabilities.

After recovery of the patients, parents and doctors will rate their overall satisfaction by using simple image of 5 point Likert scale.

Primary outcome: effectiveness of sedation. Secondary outcome: onset, duration of sedation, adverse effect, parents and doctor satisfaction.

End point of the study: if our technique failed to sedate the patients general anesthesia will be given either intravenous ketamine 1mg/kg or inhalational sevoflurane to complete the procedure.

Being tested
Ketamine + midazolam
Keywords
nasal, sedation, developmental delay
Medical subject headings
Learning Disabilities

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ketamine + midazolamDrug

    Also called ketalar +dormicum

    Group IN received intranasal midazolam (0.2 mg/kg) +ketamine (5mg/kg). Group IM received intramuscular midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.

Study groups in NCT03860831
Study groupRoleWhat they receive
intranasal (IN)ExperimentalGroup IN will receive nasal ketamine+midazolam mixture by mucosal atomisation device: midazolam (0.2 mg/kg) +ketamine (5mg/kg). the calculated dose will be equally divided into the two nostrils by the parents
Receives: Drug: Ketamine + midazolam
intramuscular (IM)Active comparatorGroup IM will receive intramuscular administration of liquid ketamine +midazolam mixture:midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region. Mild to moderate restraint was done with the help of the parents during drug administration.
Receives: Drug: Ketamine + midazolam

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. change in sedation level after intranasal or intramuscular ketamine midazolam mixture administration.

    sedation level measured by Pediatric Sedation State Scale (PSSS): State 5: Movement impedes procedure and requires forceful immobilization

    State 4: Movement requires gentle immobilization for positioning

    State 3: Facial expression of pain or anxiety

    State 2: Quiet, not moving, no frown, no verbalization of complaint (ideal state)

    State 1: Deeply asleep with normal vital signs, but requires airway intervention or assistance (e.g., central or obstructive apnea)

    State 0: Deeply asleep with abnormal physiologic parameters that require acute intervention (e.g., O2 saturation <90%, hypotension, bradycardia)

    highest score is 0 and least score is 5

    Measured: every 10 minutes through the study till one hour after administration

Secondary outcomes (1)
  1. parents satisfaction

    image form of 5 point likert scale. 5-very satisfied 4-Satisfied 3-Neither satisfied nor dissatisfied 2-Dissatisfied

    1-Very dissatisfied least score is 1 and highest score is 5

    Measured: two hours after administration

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2019
  2. Study start6 Mar 2019
  3. Primary completionJun 2019 (estimated)
  4. Study completionJul 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
2 groups of children aged 4-12 years with mental disabilities(autism,down syndrome,cerebral palsy)
Masking
Double blind
Who is masked
Care provider, Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03860831
Sponsor's protocol ID
R 57/2018
Status last verified
Mar 2019
First submitted
12 Nov 2018
Last updated
8 Mar 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Malamed SF. Sedation: A Guide to Patient Management. New York, NY: CV: Mosby-Year Book Inc; 1995. 3rd ed.

  • Lee-Kim SJ, Fadavi S, Punwani I, Koerber A. Nasal versus oral midazolam sedation for pediatric dental patients. J Dent Child (Chic). 2004 May-Aug;71(2):126-30.

    PubMed 15587094
  • Ochs-Ross R,et al. Efficacy and safety of intranasal esketamine plus an oral antidepressant in eldely patients with treatment-resistant depression.Poster PS066 presented at CINP 2018,16-19 june, Vienna, Austria.

  • Dallimore D, Herd DW, Short T, Anderson BJ. Dosing ketamine for pediatric procedural sedation in the emergency department. Pediatr Emerg Care. 2008 Aug;24(8):529-33. doi: 10.1097/PEC.0b013e318180fdb5.

    PubMed 18645539
  • Cravero JP, Askins N, Sriswasdi P, Tsze DS, Zurakowski D, Sinnott S. Validation of the Pediatric Sedation State Scale. Pediatrics. 2017 May;139(5):e20162897. doi: 10.1542/peds.2016-2897.

    PubMed 28557732

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Ketamine + midazolam in people with Procedural Sedation, run by Ain Shams University at 2 sites in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 8 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact dean of faculty of medicine, MD (0020224821894, dean@med.asu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

change in sedation level after intranasal or intramuscular ketamine midazolam mixture administration. (time frame: every 10 minutes through the study till one hour after administration). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03860831, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Mar 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in